• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DRD2 Gene Record

  • Summary
  • Interactions
  • Claims
  • DRD2 1813 Druggable Genome

    Alternate Names:

    1813
    DOPAMINE RECEPTOR D2
    DRD2
    D2DR
    D2R
    126450
    3023
    ENSG00000149295
    OTTHUMG00000167717
    Dopamine D2 receptor
    D(2) dopamine receptor
    DRD2_HUMAN
    P14416
    PA27478
    D(2) DOPAMINE RECEPTOR (DOPAMINE D2 RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14416]
    T67162

    Gene Info:

    Interpro Name GPCR, rhodopsin-like, 7TM
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Acc IPR000276
    Human Readable Name G PROTEIN COUPLED RECEPTOR
    Interpro Type Family
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin
    Target Main Class Receptors
    Transmembrane Helix Count 7
    Gene Biotype PROTEIN_CODING
    (9 More Sources)

    Gene Categories: Category Details

    G PROTEIN COUPLED RECEPTOR
    DRUGGABLE GENOME

    Publications:

    Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
    Tadori et al., 2011, Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors., Eur. J. Pharmacol.
    Citrome, 2011, Role of sublingual asenapine in treatment of schizophrenia., Neuropsychiatr Dis Treat
    Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
    Blasi G et al., 2015, Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics., Neuropsychopharmacology
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
    Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
    Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
    Houston J et al., 2011, Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women., Psychiatry Res
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
    Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
    Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
    Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
    Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
    Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
    Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
    Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
    Thacker et al., 2006, The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole., Eur. J. Neurosci.
    Weizman et al., 2003, The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms., Eur. J. Pharmacol.
    Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
    Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
    Jordan et al., 2007, In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling., J. Psychopharmacol. (Oxford)
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
    Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
    Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
    Green et al., 2002, Treatment of schizophrenia and comorbid substance use disorder., Curr Drug Targets CNS Neurol Disord
    Stonehouse et al., 2005, Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum., J. Mol. Neurosci.
    Takano et al., 2006, Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
    Rascol O et al., 2007, Dopamine agonists., Handb Clin Neurol
    de Mey et al., 1991, Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist., Br J Clin Pharmacol
    Iida et al., 1999, Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist., Brain Res.
    Matsukawa et al., 2007, Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats., Brain Res.
    Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
    Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
    Shill HA et al., 2009, Update on ropinirole in the treatment of Parkinson's disease., Neuropsychiatr Dis Treat
    Mørk et al., 2009, Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved., Psychopharmacology (Berl.)
    Cincotta et al., 2010, Emerging role of sertindole in the management of schizophrenia., Neuropsychiatr Dis Treat
    Lindström et al., 2006, Sertindole: efficacy and safety in schizophrenia., Expert Opin Pharmacother
    Seeman, 2008, Dopamine D2(High) receptors moderately elevated by sertindole., Synapse
    Cavallotti et al., Age-related changes in dopamine D2 receptors in rat heart and coronary vessels., Clin. Exp. Pharmacol. Physiol.
    Jaber et al., 1994, Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary., Brain Res. Mol. Brain Res.
    Newman AH et al., 2012, Molecular determinants of selectivity and efficacy at the dopamine D3 receptor., J Med Chem
    Auclair et al., 2007, Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats., Psychopharmacology (Berl.)
    Newman-Tancredi et al., 2007, Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics., Curr Opin Investig Drugs
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Lang et al., 1995, Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis., Clin Neuropharmacol
    Kumar B et al., 2018, Lumateperone: a new treatment approach for neuropsychiatric disorders., Drugs Today (Barc)
    Kongsamut et al., 1996, Iloperidone binding to human and rat dopamine and 5-HT receptors., Eur. J. Pharmacol.
    Hesselink, 2002, Iloperidone (Novartis)., IDrugs
    Vinar et al., 1967, Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial., Act Nerv Super (Praha)
    Platz et al., 1967, Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine)., Dis Nerv Syst
    Bora, 1968, Comparison of dosage ranges of carphenazine and trifluoperazine in elderly chronic schizophrenics., Dis Nerv Syst
    Fuller et al., 1985, Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonists., J. Pharm. Pharmacol.
    Mehta et al., 2006, Dopaminergic enhancement of cognitive function., Curr. Pharm. Des.
    Paturle et al., 1987, Cortical ablation fails to influence striatal dopamine target cell supersensitivity induced by nigrostriatal denervation in the rat., Brain Res.
    Huettl et al., 1991, Effects of dopamine receptor agonists and antagonists on catecholamine release in bovine chromaffin cells., J. Pharmacol. Exp. Ther.
    Linazasoro et al., Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET., Clin Neuropharmacol
    Inoue et al., 1997, Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum., Eur. J. Pharmacol.
    Wood et al., 2007, Aripiprazole acts as a selective dopamine D2 receptor partial agonist., Expert Opin Investig Drugs
    Hirose et al., 2005, Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist., J. Med. Invest.
    Wood et al., 2006, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties., Eur. J. Pharmacol.
    Kim et al., 2006, Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study., Hum Psychopharmacol
    Lawler CP et al., 1999, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes., Neuropsychopharmacology
    Huertas E et al., 2010, The D2 dopamine receptor gene variant C957T affects human fear conditioning and aversive priming., Genes Brain Behav
    Hirvonen MM et al., 2009, C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity., Synapse
    Betcheva ET et al., 2009, Case-control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population., J Hum Genet
    Crettol S et al., 2008, Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment., Prog Neuropsychopharmacol Biol Psychiatry
    Allen NC et al., 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database., Nat Genet
    Hoenicka J et al., 2006, C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients., Acta Psychiatr Scand
    Hänninen K et al., 2006, Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia., Neurosci Lett
    Lawford BR et al., 2005, The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia., Schizophr Res
    de Bartolomeis A et al., 2015, Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism., CNS Drugs
    Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
    Zappia et al., 2005, Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study., Arch. Neurol.
    Kovoor et al., 2005, D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways., J. Neurosci.
    Mori et al., 2005, Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice., Neurosci. Res.
    Onofrj et al., 2008, An expert opinion on safinamide in Parkinson's disease., Expert Opin Investig Drugs
    Koller et al., 1998, Mechanism of action of dopaminergic agents in Parkinson's disease., Neurology
    Deleu et al., 2002, Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease., Clin Pharmacokinet
    Dupre et al., 2007, The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat., Brain Res.
    Dahlöf et al., 1998, Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?, Cephalalgia
    Hammer, Gastroesophageal reflux and prokinetic agents., Neonatal Netw
    Chemnitius et al., Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood., Pharmacol. Res.
    See et al., 1996, Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats., Neuroscience
    Kishibayashi et al., 1995, Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats., Jpn. J. Pharmacol.
    Harrold et al., 1993, The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor., J. Med. Chem.
    Bartolini A et al., 2011, Analgesic and antineuropathic drugs acting through central cholinergic mechanisms., Recent Pat CNS Drug Discov
    Tashiro M et al., 2014, Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients., Clin Chim Acta
    Callan et al., 2008, Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial., J Emerg Med
    Vinson, 2006, Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine., J Emerg Med
    Roberge, 2006, Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch., J Emerg Med
    Narita et al., 2008, Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer., Eur. J. Pharmacol.
    Hamik et al., 1989, Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors., Cancer Chemother. Pharmacol.
    Golembiewski et al., 2006, Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting., J. Perianesth. Nurs.
    Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.
    Nilsson et al., 1996, Inverse agonism at dopamine D2 receptors. Haloperidol-induced prolactin release from GH4C1 cells transfected with the human D2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine., Neuropsychopharmacology
    Ogren et al., 1984, Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain., Eur. J. Pharmacol.
    Reimold et al., 2007, Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol., Psychopharmacology (Berl.)
    Ishiwata et al., 2006, A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors., Ann Nucl Med
    Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
    Bustillo et al., 2006, Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels., Neuropsychopharmacology
    Osinski et al., 2005, Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets., Pharmacol. Biochem. Behav.
    Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
    Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
    Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
    Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
    Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
    Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
    Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
    Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
    Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
    Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
    Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
    Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
    Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
    Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
    Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
    Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
    Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
    Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
    Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
    Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
    Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
    Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
    Kroeze et al., 2003, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs., Neuropsychopharmacology
    Oades et al., 2000, Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy., Behav Pharmacol
    Wu et al., 2006, Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients., Acta Pharmacol. Sin.
    Roth et al., 1995, D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs., Psychopharmacology (Berl.)
    Roth et al., 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors., J. Pharmacol. Exp. Ther.
    Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
    Kapur et al., 2000, A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy., Arch. Gen. Psychiatry
    Innis et al., 1992, Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates., Synapse
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Tam et al., 1984, Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes., Proc. Natl. Acad. Sci. U.S.A.
    Hallikainen et al., 2003, Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males., Am. J. Med. Genet. A
    Comings DE et al., 1994, The dopamine D2 receptor gene: a genetic risk factor in substance abuse., Drug Alcohol Depend
    Balldin J et al., 2018, TAQ1A1 Allele of the DRD2 Gene Region Contribute to Shorter Survival Time in Alcohol Dependent Individuals When Controlling for the Influence of Age and Gender. A Follow-up Study of 18 Years., Alcohol Alcohol
    Ragia G et al., 2016, Association study of DRD2 A2/A1, DRD3 Ser9Gly, DβH -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence., Drug Metab Pers Ther
    Pieters S et al., 2012, The moderating effect of alcohol-specific parental rule-setting on the relation between the dopamine D2 receptor gene (DRD2), the μ-opioid receptor gene (OPRM1) and alcohol use in young adolescents., Alcohol Alcohol
    Bolos AM et al., 1990, Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism., JAMA
    Blomqvist O et al., 2000, Family-based study of DRD2 alleles in alcohol and drug dependence., Am J Med Genet
    Town T et al., 1999, Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency., Am J Med Genet
    Dooley M et al., 1998, Pramipexole. A review of its use in the management of early and advanced Parkinson's disease., Drugs Aging
    Chernoloz O et al., 2012, Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain., J Psychiatry Neurosci
    Piercey MF, 1998, Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease., Clin Neuropharmacol
    Kang SG et al., 2015, DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment., J Clin Psychopharmacol
    Rosenzweig et al., 2002, A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers., Hum Psychopharmacol
    Horacek et al., 2006, Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia., CNS Drugs
    Kalkman et al., 1998, Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat., Eur. J. Pharmacol.
    Lee et al., 1984, Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain., Psychiatry Res
    Hjerde et al., 2005, Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor., Eur J Med Chem
    Froimowitz et al., 1997, The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists., Drug Des Discov
    Froimowitz et al., 1993, Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists., J. Med. Chem.
    Ostadali et al., 2004, The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR., Iran J Allergy Asthma Immunol
    Nakamura et al., 2001, Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism., Eur. J. Pharmacol.
    Creese I et al., 1996, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs., J Neuropsychiatry Clin Neurosci
    Chokhawala K et al., 2020, Antipsychotic Medications,
    Horn AS et al., 1975, Dopamine receptor blockade and the neuroleptics, a crystallographic study., J Pharm Pharmacol
    Ali et al., 2006, Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods., Talanta
    Høyberg et al., 1993, Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations., Acta Psychiatr Scand
    Talvik et al., 2004, A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration., Psychopharmacology (Berl.)
    Farde et al., 1989, D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics., Psychopharmacology (Berl.)
    Qin et al., 1994, Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra., Eur. J. Pharmacol.
    Lidow et al., 1997, Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs., J. Pharmacol. Exp. Ther.
    Seeman et al., 1998, Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors., Mol. Psychiatry
    Puglisi-Allegra S et al., 1994, Post-training minaprine enhances memory storage in mice: involvement of D1 and D2 dopamine receptors., Psychopharmacology (Berl)
    Maeda et al., 2014, Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator., J. Pharmacol. Exp. Ther.
    Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry
    Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.
    Kopecek et al., 2005, Ziprasidone-induced galactorrhea: a case report., Neuro Endocrinol. Lett.
    Lucht et al., 2001, Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal., Pharmacogenetics
    Yamada, 2000, [Disruption of prepulse inhibition of acoustic startle as an animal model for schizophrenia]., Nihon Shinkei Seishin Yakurigaku Zasshi
    Yamada et al., 1999, Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats., Biol. Psychiatry
    Berlin et al., 2000, Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor., Int. J. Neuropsychopharmacol.
    Kim et al., 2001, The localization of dopamine D2 receptor mRNA in the human placenta and the anti-angiogenic effect of apomorphine in the chorioallantoic membrane., Life Sci.
    LeWitt PA, 2004, Subcutaneously administered apomorphine: pharmacokinetics and metabolism., Neurology
    Pastor et al., 2003, [Cabergoline in the treatment of Parkinson's disease]., Neurologia
    Linazasoro et al., Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease., Clin Neuropharmacol
    Miyagi et al., 1996, Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents., Biol. Pharm. Bull.
    Lombardi et al., 2002, Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress., Eur. J. Pharmacol.
    Kageyama et al., 2002, A case of macroprolactinoma with subclinical growth hormone production., Endocr. J.
    Ichikawa et al., 2001, [Pharmacological effects of cabergoline against parkinsonism]., Nippon Yakurigaku Zasshi
    Curran et al., 2004, Cabergoline : a review of its use in the treatment of Parkinson's disease., Drugs
    Briani et al., 2004, Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade., Eur. J. Neurol.
    Citrome, 2013, Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability., Expert Opin Drug Metab Toxicol
    Kühhorn J et al., 2011, Development of a bivalent dopamine D₂ receptor agonist., J Med Chem
    Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem
    Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem
    Molero A et al., 2015, A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors., Eur J Med Chem
    Tschammer N et al., 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions., J Med Chem
    Pagerols M et al., 2017, Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder., Pharmacogenomics J
    Regenthal et al., 2005, D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients., Int J Clin Pharmacol Ther
    Cohen, Risperidone., Pharmacotherapy
    Megens et al., 1994, Survey on the pharmacodynamics of the new antipsychotic risperidone., Psychopharmacology (Berl.)
    Remington et al., 2006, A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone., Am J Psychiatry
    Yamada et al., 2002, Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy., Synapse
    Scatton et al., 2001, The preclinical pharmacologic profile of tiapride., Eur. Psychiatry
    Pache et al., 2003, Buspirone differentially modifies short-term memory function in a combined delayed matching/non-matching to position task., Eur. J. Pharmacol.
    Nader et al., 1993, Interactions of buspirone or gepirone with nicotine on schedule-controlled behavior of pigeons., Behav Pharmacol
    Malt et al., 2003, Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls., J Affect Disord
    Boido et al., 2001, Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes., Farmaco
    Fernández-Pérez et al., 2005, Co-administration of fluoxetine and WAY100635 improves short-term memory function., Eur. J. Pharmacol.
    Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
    Murphy et al., 1999, Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists., Steroids
    Freedman et al., 1994, Expression and pharmacological characterization of the human D3 dopamine receptor., J. Pharmacol. Exp. Ther.
    Zarrindast et al., 1994, On the mechanisms by which theophylline changes core body temperature in mice., Eur. J. Pharmacol.
    Muscat et al., 1990, Dopaminergic mechanism of imipramine action in an animal model of depression., Biol. Psychiatry
    Silva et al., 2003, Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats., Pharmacol. Toxicol.
    Lahti et al., 1993, Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications., Eur. J. Pharmacol.
    Seeman et al., 1976, Antipsychotic drug doses and neuroleptic/dopamine receptors., Nature
    Schmidt et al., 1991, Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure., Psychiatry Res
    Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
    Schulze M et al., 2009, Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities?, Bioorg Med Chem
    Lane et al., 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function., Int. J. Neuropsychopharmacol.
    Fenton et al., 2005, Risperidone: a review of its use in the treatment of bipolar mania., CNS Drugs
    Catafau et al., 2006, Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response., Psychiatry Res
    Corena-McLeod M, 2015, Comparative Pharmacology of Risperidone and Paliperidone., Drugs R D
    von Coburg et al., 2009, Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics., Bioorg. Med. Chem. Lett.
    Fux et al., 1991, A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia., Isr J Psychiatry Relat Sci
    Burstein et al., 2005, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist., J. Pharmacol. Exp. Ther.
    Choi et al., 2004, Synthesis, receptor binding and functional studies of mesoridazine stereoisomers., Bioorg. Med. Chem. Lett.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Nyberg et al., 1995, Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans., Int Clin Psychopharmacol
    Gareri et al., 2003, Conventional and atypical antipsychotics in the elderly : a review., Clin Drug Investig
    Lublin et al., 1991, Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia., Eur Neuropsychopharmacol
    Seeman, 1990, Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage., Acta Psychiatr Scand Suppl
    Carey et al., 1997, Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs., Psychopharmacology (Berl.)
    Assié et al., 1993, Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics., Eur. J. Pharmacol.
    Barth et al., 2006, Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer., Life Sci.
    Dimpfel et al., 1992, Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats., Psychopharmacology (Berl.)
    Nasu et al., 2000, Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice., Biopharm Drug Dispos
    Wei et al., 1990, [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]., Yao Xue Xue Bao
    Bartoszyk GD et al., 2004, Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile., J Neural Transm (Vienna)
    George et al., 2013, Newer antipsychotics and upcoming molecules for schizophrenia., Eur. J. Clin. Pharmacol.
    Schotte et al., 1996, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding., Psychopharmacology (Berl.)
    Wang, 2002, Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes)., Synapse
    Cannon JG et al., 1986, p-Dimethoxy-substituted trans-octahydrobenzo[f]- and -[g]quinolines: synthesis and assessment of dopaminergic agonist effects., J Med Chem
    Mouly S et al., 2015, Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity., Br J Clin Pharmacol
    Levran O et al., 2013, Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction., Pharmacogenomics
    Hung CC et al., 2011, Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients., Pharmacogenomics
    Green et al., 2004, Focus on levomepromazine., Curr Med Res Opin
    Dahl et al., 1986, Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding., Biochem. Pharmacol.
    Larson, 2003, The effect of antiemetics on pupillary reflex dilation during epidural/general anesthesia., Anesth. Analg.
    Gao et al., 2010, The effect of dopamine on pain-related neurons in the parafascicular nucleus of rats., J Neural Transm (Vienna)
    Grip et al., 1992, Histopathology and evaluation of potentiation of morphine-induced antinociception by intrathecal droperidol in the rat., Acta Anaesthesiol Scand
    Holtmann et al., 2006, A placebo-controlled trial of itopride in functional dyspepsia., N. Engl. J. Med.
    Choung et al., 2007, A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers., Neurogastroenterol. Motil.
    Deeks ED et al., 2010, Blonanserin: a review of its use in the management of schizophrenia., CNS Drugs
    Kim DH et al., 2009, Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia., Neurotherapeutics
    Adolph O et al., 2012, Promethazine inhibits NMDA-induced currents - new pharmacological aspects of an old drug., Neuropharmacology
    Strange PG, 2008, Antipsychotic drug action: antagonism, inverse agonism or partial agonism., Trends Pharmacol Sci
    Rouge-Pont et al., 2002, Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors., J. Neurosci.
    Lahlou, 1999, Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats., Fundam Clin Pharmacol
    Lahlou et al., 2003, Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats., Pharmacol. Toxicol.
    Stefaneanu et al., 2001, Dopamine D2 receptor gene expression in human adenohypophysial adenomas., Endocrine
    Lahlou et al., 2000, Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats., Can. J. Physiol. Pharmacol.
    Cinciripini P et al., 2004, The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood., Nicotine Tob Res
    Shultz et al., 1987, Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells., Am. J. Physiol.
    Dziedzicka-Wasylewska et al., 1996, The effect of prolonged administration of lithium on the level of dopamine D2 receptor mRNA in the rat striatum and nucleus accumbens., Acta Neurobiol Exp (Wars)
    Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
    Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
    Langlois X et al., 2012, Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia., J Pharmacol Exp Ther
    Spellicy CJ et al., 2013, ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse., Pharmacogenet Genomics
  • NEMONAPRIDE   DRD2

    Interaction Score: 7.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918131 9858029 28673279 20194480 17105675 16513877 15694263 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11505224 11329406 10862524 10823405


    Sources:
    PharmGKB TTD

  • CABERGOLINE   DRD2

    Interaction Score: 5.25

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Dopamine D2 receptor agonist

    PMIDs:
    18808942 12721865 18303487 8951172 12464354 12008749 11752352 11436517 15341508


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • PERGOLIDE   DRD2

    Interaction Score: 1.62

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    18808942 2860228 16842172 11752352 3828803 1674528 18691132 10516878 10641988


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • JNJ-37822681   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name JNJ-37822681
    Novel drug target Established target

    PMIDs:
    22490380


    Sources:
    TdgClinicalTrial TTD

  • PRIDOPIDINE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Novel drug target Established target
    Trial Name pridopidine, ACR-16,Huntexil
    Mechanism of Interaction Dopamine D2 receptor modulator

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • PRAMIPEXOLE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Mirapex
    Novel drug target Established target

    PMIDs:
    18691132 10641988 11752352 9638397 22023785 9617505


    Sources:
    TdgClinicalTrial TEND TTD

  • ARIPIPRAZOLE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Abilify
    Novel drug target Established target
    Mechanism of Interaction Dopamine D2 receptor partial agonist

    PMIDs:
    9083792 17501690 11752352 16366516 16925992 16981227 9918131 28673279 20194480 10327430 991813 9858029 9713903 19900188 19582781 19158809 18926547 18687376 18583979 17105675 17087792 16973280 16513877 16123753 15830237 15694263 15567074 14610521 11920858 11505224 26346901


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ROPINIROLE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name JZP-7
    Novel drug target Established target
    Trial Name ReQuip

    PMIDs:
    18808942 1683559 10446316 17573046 11752352 18691132 10641988 19557097


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • BROMPERIDOL   DRD2

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 15694263 11505224


    Sources:
    PharmGKB

  • MOLINDONE   DRD2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    9353417 9577836 17016423 9342550 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • ACETOPHENAZINE   DRD2

    Interaction Score: 1.0

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752352 11873706 17016423 17139284 6147851


    Sources:
    TdgClinicalTrial TEND TTD

  • THIOTHIXENE   DRD2

    Interaction Score: 0.84

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    11103886 16867246 20643630 15694263 11873706 3039860 11752352


    Sources:
    ChemblInteractions TTD

  • 5-OH-DPAT   DRD2

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3783613


    Sources:
    DTC

  • BUPROPION   DRD2

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123753 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405


    Sources:
    PharmGKB

  • LOXAPINE   DRD2

    Interaction Score: 0.69

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name AZ-004
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    9570468 6239298 15694653 8665533 9342550 11752352 8101879


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • FLUPENTIXOL   DRD2

    Interaction Score: 0.67

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    7498321 8797192 6149133 11873706 11752352 1674528 17111172 21421319


    Sources:
    DTC

  • CARPHENAZINE   DRD2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    4889058 4861216 11752352 4887393


    Sources:
    TdgClinicalTrial TEND TTD

  • LISURIDE   DRD2

    Interaction Score: 0.62

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    18691132 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • DOMPERIDONE   DRD2

    Interaction Score: 0.6

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12010185 15894081 1683559 18970411 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • MESORIDAZINE   DRD2

    Interaction Score: 0.56

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16135699 15357957 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • ZUCLOPENTHIXOL   DRD2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8748043 17535043 11752352 1822319


    Sources:
    TdgClinicalTrial TEND TTD

  • DROPERIDOL   DRD2

    Interaction Score: 0.5

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    14633536 20358234 1549935 2527092


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • QUINPIROLE   DRD2

    Interaction Score: 0.45

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    21999579 26164842 21536445 25969169 21388142


    Sources:
    DTC

  • RISPERIDONE   DRD2

    Interaction Score: 0.44

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Trial Name -

    PMIDs:
    16730699 15140279 16513859 15907153 11752352 17059881 11132243 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 10395223 991813 9858029 9713903 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 17105675 16513877 16123753 15830237 15694263 15492764 15286066 15184239 15146457 15077009 14610521 12587665 11920858 11505224 11329406 10862524 10823405 21421319 25943458


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • CHLORPROTHIXENE   DRD2

    Interaction Score: 0.43

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Trial Name -

    PMIDs:
    19091563 8101879 1830565 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • PALIPERIDONE   DRD2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name paliperidone ER, paliperidone palmitate
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    16119512 7524043 7531353 16513859 11752352 11132243 12211096


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • DOCARPAMINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • QUINAGOLIDE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SERIDOPIDINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor modulator
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIETHYLPERAZINE MALEATE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BL-1020   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • APLINDORE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Aplindore, DAB-452
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • RASAGILINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27190009


    Sources:
    PharmGKB

  • BENZQUINAMIDE HYDROCHLORIDE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor modulator

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DENOPAMINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DOPEXAMINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ACETOPHENAZINE MALEATE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BLONANSERIN   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    20030420


    Sources:
    TTD

  • ITOPRIDE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name itopride,Itax
    Novel drug target Established target

    PMIDs:
    16495395 17300287


    Sources:
    TdgClinicalTrial

  • APLINDORE FUMARATE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor partial agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SARIZOTAN   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:

    PMIDs:
    14767715


    Sources:
    TTD

  • STEPHOLIDINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19744859


    Sources:
    DTC

  • BUSPIRONE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    14522358 11224194 12781354 11421254 16214127


    Sources:
    TdgClinicalTrial TEND

  • TIAPRIDE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:

    PMIDs:
    11520476


    Sources:
    TTD

  • ORDOPIDINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor modulator

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FLUPHENAZINE ENANTHATE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CARIPRAZINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name cariprazine, RGH-188
    Novel drug target Established target

    PMIDs:
    23320989


    Sources:
    TdgClinicalTrial TTD

  • CARMOXIROLE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • FLUPHENAZINE DECANOATE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRIFLUPROMAZINE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    17016423 17139284 9081563 30137788 239169


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • SUMANIROLE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SULPIRIDE   DRD2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    12010185 11752352 7518029 22632094


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • CHLORPROMAZINE   DRD2

    Interaction Score: 0.36

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    11103886 16867246 20643630 15694263 8524985 11873706 11752352 7908055 9918131 9858029 28673279 20194480 18926547 17105675 16513877 15830237 11505224


    Sources:
    ChemblInteractions PharmGKB TTD

  • METOCLOPRAMIDE   DRD2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name MT 100
    Trial Name metoclopramide,Emitasol, Pramidin
    Trial Name metoclopramide HCl,Metzoliv ODT

    PMIDs:
    9876882 15835479 8981558 8730709 7745844 8230103 11752352 21585331


    Sources:
    TdgClinicalTrial TEND TTD

  • AMISULPRIDE   DRD2

    Interaction Score: 0.33

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name amisulpride,Solian
    Novel drug target Established target
    Trial Name APD421

    PMIDs:
    25679126 12404702 11873706 16696579


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • APOMORPHINE   DRD2

    Interaction Score: 0.32

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name apomorphine HCl,Uprima, Ixense
    Novel drug target Established target
    Trial Name apomorphine hydrochloride,Apokyn, APO-go

    PMIDs:
    11692072 11215397 10494453 11343576 11752352 11212866 18691132 10641988 15037665


    Sources:
    TdgClinicalTrial TEND TTD

  • MINAPRINE   DRD2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 7862862


    Sources:
    TdgClinicalTrial TEND

  • REMOXIPRIDE   DRD2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11873706 8665533 11752352


    Sources:
    TdgClinicalTrial TEND

  • BREXPIPRAZOLE   DRD2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor partial agonist
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    24947465


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • ROTIGOTINE   DRD2

    Interaction Score: 0.3

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Neupro
    Novel drug target Established target
    Mechanism of Interaction D2-like dopamine receptor agonist

    PMIDs:
    18691132


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • HALOPERIDOL   DRD2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inverse agonist (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Trial Name -

    PMIDs:
    17134027 7520908 16132064 16730699 15894081 20643630 17316700 11752352 12887421 21421319 27023437 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405 12629531


    Sources:
    DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

  • BROMOCRIPTINE   DRD2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name bromocriptine mesylate,Cycloset, Ergoset
    Novel drug target Established target

    PMIDs:
    12010185 10626749 11752352 12753422 11444429 10721819 18691132 10641988


    Sources:
    TdgClinicalTrial TEND TTD

  • OCAPERIDONE   DRD2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    TTD

  • PERPHENAZINE   DRD2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Direct Interaction yes

    PMIDs:
    7508675 15007534 2573104 11873706 11752352 7828655


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • BIFEPRUNOX   DRD2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor partial agonist
    Direct Interaction yes
    Trial Name bifeprunox, DU127090

    PMIDs:
    17393144 17659474


    Sources:
    TdgClinicalTrial ChemblInteractions

  • CLOZAPINE   DRD2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    12887421 9918131 28673279 26872113 23859574 23851570 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 15286066 14575800 12769622 11752352 15781964 16040180 21421319


    Sources:
    DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB

  • SERTINDOLE   DRD2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    19506838 20856607 11752352 16925508 18293356


    Sources:
    TdgClinicalTrial TEND

  • LURASIDONE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name lurasidone, SM-13496,Latuda
    Novel drug target Established target

    PMIDs:
    23545936


    Sources:
    TdgClinicalTrial TEND

  • THIORIDAZINE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    1978482 9292626 7689973 16434058 1352051


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • FLUPHENAZINE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11873706 7508675 11752352 7828655


    Sources:
    TdgClinicalTrial TEND

  • LUMATEPERONE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    partial agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ITI-007, ITI-722
    Novel drug target Established target
    Mechanism of Interaction Dopamine D2 receptor partial agonist

    PMIDs:
    30596390


    Sources:
    TdgClinicalTrial ChemblInteractions

  • OLANZAPINE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    9918131 28673279 26872113 25563748 23859574 23851570 22967772 21095016 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 17067304 14575800 16730699 17316700 17092971 11752352 17848919 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • PROCHLORPERAZINE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name AZ-001, Staccato prochlorperazine
    Novel drug target Established target
    Trial Name buccal prochlorperazine maleate,Emezine

    PMIDs:
    24360851 18534808 17044574 16677982 11752352 18955042 2527092 17169748


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • THIETHYLPERAZINE   DRD2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    15469457 17016423 17139284


    Sources:
    TdgClinicalTrial TEND TTD

  • SB-773812   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • UMESPIRONE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • MOLINDONE HYDROCHLORIDE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TALIPEXOLE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • RISPERDAL   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Risperdal
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • PERAZINE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PROPIOMAZINE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 19110200 22507664 18471899


    Sources:
    TdgClinicalTrial TEND

  • PROCHLORPERAZINE MALEATE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MESORIDAZINE BESYLATE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TOLAZOLINE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CARIPRAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    modulator

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor modulator

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ABAPERIDONE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NAPHAZOLINE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BEVANTOLOL   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • LURASIDONE HYDROCHLORIDE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ZIPRASIDONE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ziprasidone HCl, ziprasidone mesylate,Geodon, Zeldox
    Novel drug target Established target

    PMIDs:
    14728084 11873706 7562537 11752352 17848919 15726024


    Sources:
    TdgClinicalTrial TEND TTD

  • MEPHENTERMINE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ASENAPINE MALEATE   DRD2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • FLUSPIRILENE   DRD2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8935801 11752352 17139284 11842444 17016423


    Sources:
    TdgClinicalTrial TEND TTD

  • PIMOZIDE   DRD2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor antagonist
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    7855217 10503726 8301582 8082693 2378927 11873706 12828573 11752352


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • PARDOPRUNOX   DRD2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine receptors; D2 & D3 partial agonist
    Trial Name pardoprunox, SLV 308

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • ANIRACETAM   DRD2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11412837


    Sources:
    TTD

  • ILOPERIDONE   DRD2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes
    Novel drug target Established target

    PMIDs:
    8997630 12861482


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • QUETIAPINE   DRD2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Seroquel
    Novel drug target Established target

    PMIDs:
    21421319 11132243 11873706 17848919 11752352 10839333


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • LEVOMEPROMAZINE   DRD2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    10592235 15701205 2870716


    Sources:
    ChemblInteractions TTD

  • PROMAZINE   DRD2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 19110200 18471899


    Sources:
    TdgClinicalTrial TEND

  • ZIPRASIDONE MESYLATE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • QUETIAPINE FUMARATE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ARIPIPRAZOLE LAUROXIL   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor partial agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DEXPRAMIPEXOLE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name dexpramipexole, KNS-760704
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • PRAMIPEXOLE DIHYDROCHLORIDE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIOTHIXENE HYDROCHLORIDE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPHEDRINE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METOCLOPRAMIDE HYDROCHLORIDE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PIPERACETAZINE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • APOMORPHINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ERGONOVINE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRIFLUOPERAZINE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8102973 945467 1676523 11873706 15695070 11752352


    Sources:
    TdgClinicalTrial TEND

  • CARPHENAZINE MALEATE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROXINDOLE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ZIPRASIDONE HYDROCHLORIDE   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LEVODOPA   DRD2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name DM-1992
    Novel drug target Established target
    Trial Name entacapone/levodopa/carbidopa,Stalevo

    PMIDs:
    27779245 15824260 15728856 15710490 18549347 9633680 11978145 17553470


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • DIHYDREXIDINE   DRD2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19744859


    Sources:
    DTC

  • ASENAPINE   DRD2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Asenapine
    Novel drug target Established target

    PMIDs:
    18308814 21658377 21655346


    Sources:
    TdgClinicalTrial TEND

  • HALOPERIDOL DECANOATE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SARIZOTAN HYDROCHLORIDE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor partial agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ZICRONAPINE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • E-FLUPENTIXOL   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • PHENYLTOLOXAMINE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • HALOPERIDOL LACTATE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor inverse agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ROPINIROLE HYDROCHLORIDE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DAPIPRAZOLE   DRD2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METHADONE   DRD2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25556837 23651024 21902500 19373123 18687376


    Sources:
    PharmGKB

  • AMOXAPINE   DRD2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    11180191 1966571


    Sources:
    ChemblInteractions

  • DIHYDROERGOTAMINE   DRD2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • OLANZAPINE PAMOATE   DRD2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ETILEVODOPA   DRD2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name etilevodopa, TV-1203

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • LOXAPINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ONC-201   DRD2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRIFLUPROMAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LOXAPINE SUCCINATE   DRD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DOPAMINE   DRD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    17301410 11752352


    Sources:
    TTD

  • AMPHETAMINE   DRD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    1532675


    Sources:
    PharmGKB

  • ALCOHOL   DRD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12749054 8033754 29236941 27447243 22798433 1979357 1969501 1839129 17989061 11054774 10490697


    Sources:
    NCI PharmGKB

  • FLUPHENAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SUMATRIPTAN   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25096645


    Sources:
    PharmGKB

  • BROMOCRIPTINE MESYLATE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PERGOLIDE MESYLATE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine receptor agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MELEVODOPA   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name V-1512, CHF-1512,Levomet Complex, Sirio

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • TRIMIPRAMINE MALEATE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Dopamine D2 receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • METARAMINOL   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PHENOXYBENZAMINE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PROMAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PROCHLORPERAZINE EDISYLATE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THIETHYLPERAZINE MALATE   DRD2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Dopamine D2 receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENTOLAMINE   DRD2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TRIFLUOPERAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ERGOLOID MESYLATES   DRD2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Dopamine receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIACETYLMORPHINE   DRD2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PHENYLEPHRINE   DRD2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • THIORIDAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MORPHINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11943831


    Sources:
    NCI

  • NICOTINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16123753 15203796


    Sources:
    PharmGKB

  • PSEUDOEPHEDRINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CHLORPROMAZINE HYDROCHLORIDE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DISULFIRAM   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23635803


    Sources:
    PharmGKB

  • COCAINE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHYLPHENIDATE   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26810137


    Sources:
    PharmGKB

  • LITHIUM   DRD2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8787189


    Sources:
    NCI

  • METHAMPHETAMINE   DRD2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • METHYLDOPA   DRD2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • Ensembl: ENSG00000149295

    • Version: 101_38

    Alternate Names:
    DRD2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P14416

    • Version: 01-August-2011

    Alternate Names:
    1813 Entrez Gene Id
    DRD2 Gene Symbol
    ENSG00000149295 Ensembl Gene Id

    Gene Info:
    Target Main Class Receptors
    Target Subclass Rhodopsin
    Transmembrane Helix Count 7

    Publications:

  • HopkinsGroom: P14416

    • Version: 11-September-2012

    Alternate Names:
    1813 Entrez Gene Id
    ENSG00000149295 Ensembl Gene Id
    D(2) DOPAMINE RECEPTOR Uniprot Protein Name

    Gene Info:
    Interpro Name GPCR, rhodopsin-like, 7TM
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000149295

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000149295 Ensembl Gene Id
    DRD2 Display Id
    D(2) DOPAMINE RECEPTOR (DOPAMINE D2 RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14416] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P14416

    • Version: January-2014

    Alternate Names:
    DRD2 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin

    Publications:

  • PharmGKB: DRD2

    • Version: 18-August-2020

    Alternate Names:
    PA27478 PharmGKB ID

    Gene Info:

    Publications:
    Rieck M et al., 2018, Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease., Pharmacogenomics J
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J

  • TTD: Dopamine D2 receptor

    • Version: 2020.06.01

    Alternate Names:
    D2R TTD Gene Abbreviation
    T67162 TTD Target ID

    Gene Info:

    Publications:
    Guo JD et al., 2009, Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes., Neuroscience

  • NCI: DRD2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
    Brené et al., 1990, Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen., Exp Brain Res
    Hallikainen et al., 2003, Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males., Am. J. Med. Genet. A

  • DTC: DRD2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Vangveravong S et al., 2011, Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound., Bioorg Med Chem
    Tschammer N et al., 2011, Highly potent 5-aminotetrahydropyrazolopyridines: enantioselective dopamine D3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions., J Med Chem
    Matera C et al., 2015, Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization., Eur J Med Chem

  • ChemblInteractions: DRD2

    • Version: chembl_23

    Alternate Names:
    DRD2 GENE_SYMBOL
    D(2) dopamine receptor UNIPROT
    Dopamine D2 receptor UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000149295

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000149295 Gene Symbol
    DRD2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • dGene: DRD2

    • Version: 27-Jun-2013

    Alternate Names:
    1813 Gene ID
    D2DR dGene Synonym
    D2R dGene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

  • GO: DRD2

    • Version: 01-February-2022

    Alternate Names:

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21